The Older Adult with Insomnia, a Benzodiazepine, and a Fall
A 74-year-old woman presents with 8 months of difficulty staying asleep, waking at 02:00-03:00 and unable to return to sleep. She has hypertension, mild knee osteoarthritis, and a prior wrist fracture from a fall. She has taken zolpidem 10 mg nightly for 6 months, prescribed by an urgent care clinician, and reports that it 'stopped working' 2 months ago. She also takes oxybutynin for urgency and lisinopril. She denies snoring, and her Epworth score is 6. She naps 90 minutes most afternoons. She is anxious about sleep and has started going to bed at 20:30 to 'try to get more sleep.'
1. List the modifiable contributors to her insomnia and explain why each matters mechanistically.
Read the worked answer
Several contributors are iatrogenic or behavioral and each has a distinct mechanism:
- Zolpidem tolerance and rebound: nightly use for 6 months produces tolerance to the hypnotic effect; the 'stopped working' history is typical. Zolpidem also increases fall risk in older adults, especially with nighttime awakenings, and is on the Beers list for this reason.
- Oxybutynin: an anticholinergic that can cause nocturia, dry mouth, and cognitive effects, and anticholinergic burden is associated with confusion and falls in older adults. Nocturia is a direct cause of sleep maintenance insomnia.
- Afternoon nap of 90 minutes: reduces homeostatic sleep pressure (adenosine accumulation) and shifts the sleep drive later, worsening sleep onset and maintenance at night.
- Advanced bedtime (20:30): extends time in bed, increases time awake in bed, and conditions arousal and frustration to the bed (classic psychophysiological insomnia). It also advances the sleep phase in a person who may already have an advanced circadian phase.
- Sleep-related anxiety and hyperarousal: cognitive arousal perpetuates the cycle.
The evaluation should also screen for depression, pain from osteoarthritis, and primary sleep disorders, but the listed factors are the highest-yield targets.
2. What is the evidence-based first-line treatment plan, and how do you handle the zolpidem?
Read the worked answer
First-line treatment for chronic insomnia in older adults is cognitive behavioral therapy for insomnia (CBT-I), which addresses sleep restriction, stimulus control, cognitive restructuring, and relaxation, and has durable benefit without fall or cognitive risk. Components here: restrict time in bed to approximate actual sleep time (e.g., start with a 23:00-06:30 window), stimulus control (bed only for sleep and intimacy; get out of bed if awake >20 min), eliminate the afternoon nap or limit it to 20-30 min before 15:00, and set a consistent wake time.
For the zolpidem: do not stop abruptly without a plan if there is concern for rebound, but the goal is deprescribing. A reasonable approach is to taper (e.g., reduce to 5 mg for 2-4 weeks, then alternate nights, then stop) while CBT-I is established, and to coordinate with her prescriber. She should be counseled that zolpidem is associated with complex sleep behaviors and falls and that the 10 mg dose exceeds recommended dosing for older adults (recommended 5 mg for women and older adults). Review oxybutynin with her primary clinician for a less anticholinergic alternative. Reassess in 2-4 weeks.
3. She asks for 'something stronger' and mentions a friend who takes trazodone. How do you counsel her, and what would you avoid?
Read the worked answer
Counsel that more hypnotic is not the answer to tolerance; the problem is the strategy, not an inadequate dose. For trazodone, the evidence for insomnia is modest and mostly from small studies; in older adults it carries orthostatic hypotension, QT prolongation, and serotonergic risk, and the 25-50 mg doses used for sleep are below antidepressant doses. It is not a first-line agent and should not be presented as a safe substitute for CBT-I.
Avoid: benzodiazepines and Z-drugs as long-term therapy in this patient (falls, fractures, cognitive impairment, dependence), sedating antihistamines (anticholinergic burden, tolerance, next-day impairment), and anticholinergic combinations with her oxybutynin. Also avoid alcohol as a sleep aid. If pharmacotherapy is needed after CBT-I, options with better geriatric profiles include low-dose doxepin (3-6 mg) for sleep maintenance or ramelteon, with monitoring; melatonin has limited evidence. The exam-relevant principle is that CBT-I is first-line at any age, and the presence of a prior fragility fracture makes fall-risk reduction a primary treatment goal.